Form 4: Artivion Executive VP Lance A. Berry Reports Stock Transactions
SEC Form 4 Filing
Executive VP and CFO Lance A. Berry reports acquisition and disposal of Artivion, Inc. stock related to performance stock units.
Summary
- On March 6, 2025, Lance A. Berry, Executive VP and CFO of Artivion, Inc., reported transactions involving the company's common stock.
- Berry acquired 48,100 shares of common stock at $0, representing performance stock units granted on February 23, 2024, with one-third vesting on March 6, 2025.
- He also disposed of 4,909 shares at $24.8042 to cover tax withholding obligations related to the vesting of these performance stock units.
- Following these transactions, Berry beneficially owns 153,431 shares of Artivion, Inc. common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are routine and related to executive compensation. The vesting of performance stock units is a positive sign, but the sale to cover taxes is a neutral event.
Positives
- The vesting of performance stock units suggests that performance targets were met, which is a positive indicator.
Negatives
- The sale of shares to cover tax obligations, while routine, slightly reduces Berry's stake in the company.
Risks
- Future vesting of performance stock units is contingent upon continued employment, creating a potential risk if Berry were to leave the company.
Future Outlook
The remaining performance stock units will vest in two tranches on February 23, 2026, and February 23, 2027, contingent upon continued employment.
Industry Context
Insider transactions are closely watched as they can provide insights into management's confidence in the company's prospects. Routine sales to cover tax obligations are common and generally not a cause for concern.
Comparison to Industry Standards
- Executive compensation packages often include performance-based equity awards to align management's interests with those of shareholders.
- Vesting schedules are typical, with multi-year vesting periods to incentivize long-term commitment.
- Similar companies in the medical device industry, such as Medtronic or Boston Scientific, also utilize equity-based compensation.
Stakeholder Impact
- The transactions have a minor impact on shareholders, as they involve a small percentage of the outstanding shares.
- The vesting of performance stock units incentivizes the executive to continue to perform well.
Key Dates
| Date | Description |
|---|---|
| February 23, 2024 | Date of the performance stock units grant. |
| March 6, 2025 | Date of stock acquisition and disposal. |
| February 23, 2026 | Next vesting date for one-third of the remaining performance stock units. |
| February 23, 2027 | Final vesting date for one-third of the remaining performance stock units. |
| March 10, 2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.